Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
1997 | 1 |
2010 | 1 |
2012 | 1 |
2013 | 1 |
2017 | 1 |
2021 | 1 |
2023 | 2 |
2024 | 1 |
Search Results
5 results
Results by year
Filters applied: Meta-Analysis, Review, Systematic Review, in the last 10 years. Clear all
Page 1
Different local estrogen therapies for a tailored approach to GSM.
Climacteric. 2023 Aug;26(4):361-366. doi: 10.1080/13697137.2023.2218998. Epub 2023 Jun 15.
Climacteric. 2023.
PMID: 37318030
Review.
Over the years, several vaginal products including different formulations (tablets, rings, capsules, pessaries, creams, gels and ovules) and molecules (estradiol [E2], estriol [E3], promestriene, conjugated equine estrogens and estrone) have been used with superimposable t …
Over the years, several vaginal products including different formulations (tablets, rings, capsules, pessaries, creams, gels and ovules) and …
Physical energies for the management of genitourinary syndrome of menopause: An overview of a systematic review and network meta-analysis.
Sarmento ACA, de Araújo Santos Camargo JD, de Freitas CL, Medeiros KS, Costa APF, Gonçalves AK.
Sarmento ACA, et al.
Int J Gynaecol Obstet. 2023 Dec 16. doi: 10.1002/ijgo.15304. Online ahead of print.
Int J Gynaecol Obstet. 2023.
PMID: 38102987
Review.
Our network meta-analysis results showed that premarin (SMD 2.60, 95% CI 7.76-3.43), conjugated estrogens (SMD 2.13, 95% CI 1.34-2.91), carbon dioxide laser (SMD 1.71, 95% CI 1.10-2.31), promestriene (SMD 1.41, 95% CI 0.59-2.24), and vaginal lubricant (SMD 1.37, 95% CI 0.5 …
Our network meta-analysis results showed that premarin (SMD 2.60, 95% CI 7.76-3.43), conjugated estrogens (SMD 2.13, 95% CI 1.34-2.91), carb …
Item in Clipboard
Local hormone therapy for genitourinary syndrome of menopause in breast cancer patients: is it safe?
Oyarzún MFG, Castelo-Branco C.
Oyarzún MFG, et al.
Gynecol Endocrinol. 2017 Jun;33(6):418-420. doi: 10.1080/09513590.2017.1290076. Epub 2017 Feb 21.
Gynecol Endocrinol. 2017.
PMID: 28277141
Review.
Item in Clipboard
Preoperative topical estrogen application in the management of hypospadias: a systematic review.
Thanneeru SK, Gupta A, Chanchlani R, Sharma PK, Babu R, Ahmad R, Agrawal A.
Thanneeru SK, et al.
Pediatr Surg Int. 2024 May 13;40(1):132. doi: 10.1007/s00383-024-05708-x.
Pediatr Surg Int. 2024.
PMID: 38739164
Review.
Item in Clipboard
Management of postmenopausal vulvovaginal atrophy: recommendations of the International Society for the Study of Vulvovaginal Disease.
Pérez-López FR, Phillips N, Vieira-Baptista P, Cohen-Sacher B, Fialho SCAV, Stockdale CK.
Pérez-López FR, et al.
Gynecol Endocrinol. 2021 Aug;37(8):746-752. doi: 10.1080/09513590.2021.1943346. Epub 2021 Jun 25.
Gynecol Endocrinol. 2021.
PMID: 34169794
Review.
Beneficial options include lubricants, moisturizers, vaginal estrogens (estradiol, estriol, promestriene, conjugated estrogens), androgens, prasterone, and laser application. ...
Beneficial options include lubricants, moisturizers, vaginal estrogens (estradiol, estriol, promestriene, conjugated estrogens), andr …
Item in Clipboard
Cite
Cite